Application of monoclonal antibodies to purified CEA in clinical radioimmunoassay of human serum

Rogers, G. T.; Rawlins, G.A.; Keep, P. A.; Cooper, E H; Bagshawe, K. D.

doi:10.1038/bjc.1981.194

Cited by 22 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the arguments for changing from an assay using a polyclonal antibody to one with a monoclonal antibody could be the expectation of greater speci- Rogers et al (9) described a monoclonal antibody with a preference for CEA in the serum of stomach carcinoma patients. Staab reported that the present Röche assay was more specific for CEA isomers from patients with colon carcinoma than the Röche radioimmunoassay with polyclonal antiserum (6).…”

Section: Discussionmentioning

confidence: 97%

Comparison of Monoclonal and Polyclonal Enzyme Immuno Assays for Carcinoembryonic Antigen

Fleuren¹,

Oers²

1986

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

A new commercially available CEA immunoassay, using monoclonal antibody, was evaluated for the purpose of routine clinical use.The between-day coefficient of Variation was 5.2% at the 6.6 g/l level and 4.1% at the 14.2 g/l level.The results of analysis of sera from 260 patients were compared with the data from an established method with polyclonal antiserum. A good correlation between the two methods was found.When the patients were classified according to groups with known types of carcinomas no systematic differences between the monoclonal and polyclonal modes of assay were apparent.Relatively large differences in serum CEA levels did occur in individuäl patients necessitating a transition period in changing from one method to the other.

show abstract

Section: Discussionmentioning

confidence: 97%

Comparison of Monoclonal and Polyclonal Enzyme Immuno Assays for Carcinoembryonic Antigen

Fleuren¹,

Oers²

1986

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Binding of purified CEA antigen, crude CRC cell extract or human plasma was highest with catcher antibodies C.20-32, Bl.l, B6.2, and 5E91E9 using MoAb 5E91E9 or C420-32 as tracer. MoAb C420-32 could trace the antigen bound by catcher MoAb B6.2, indicating that the purified Bl.l 5E91E9 0-3 3.1-6.0 6.1-13 14-25 26-50 51-100 85 22 8 CEA preparation also contained some of the low-molecular-weight CEA-related protein. MoAb B6.2 as catcher followed by MoAb C420-32 as tracer showed high binding activity when incubated with a pooled plasma sample from five healthy donors.…”

Section: Ddia For Antigen Detection In Ssfm and Human Seramentioning

confidence: 93%

Detection of Carcinoembryonic Antigen and Related Antigens in Sera of Patients with Gastrointestinal Tumors Using Monoclonal Antibodies in Double-Determinant Radioimmunoassays

Herlyn¹,

Błaszczyk²,

Sears³

et al. 1983

Hybridoma

View full text Add to dashboard Cite

Of 14 monoclonal antibodies produced in six different laboratories, 13 bound to purified preparations of carcinoembryonic antigen (CEA). All antibodies reacted to spent medium of colorectal carcinoma cell lines. Competitive binding studies indicated that 12 different antigenic determinants representing six different groups were detected on the CEA molecule(s). Six antibodies were used in double determinant radioimmunoassays (RIA) to detect CEA and CEA-related antigens in sera of 311 patients with various gastrointestinal diseases and of normal donors. None of up to 115 sera of healthy donors had elevated antigen levels with four out of the six monoclonal antibodies tested, whereas up to 9% of sera showed elevated antigen levels when tested with two antibodies. Between 1.4% and 4.4% of sera from patients with inflammatory and benign neoplastic diseases of the gastrointestinal tract were positive. Antigen levels were elevated in 56 to 75% (depending on antibody used) of sera from patients with advanced gastrointestinal tumors. These preliminary results indicate that double-determinant immunoassays with a panel of monoclonal antibodies might improve conventional CEA assays by reducing the number of false positive sera detected by polyclonal sera in patients with benign inflammatory bowel diseases.

show abstract

“…(22). On the other hand, two other groups (23,24) did not obtain increased clinical specificity or sensitivity with assays using MAbs.…”

Section: Methodsmentioning

confidence: 99%

A monoclonal antibody-enzyme immunoassay for serum carcinoembryonic antigen with increased specificity for carcinomas.

Hedin¹,

Carlsson²,

Berglund³

et al. 1983

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

A two-site monoclonal antibody-enzyme immunoassay (MEIA) for carcinoembryonic antigen (CEA) was developed that uses two monoclonal anti-CEA antibodies, which recognize two different epitopes in the peptide moiety of CEA. The assay was sensitive to 0.5 pug/liter and had a measuring range of 0.5-200 pig of CEA per liter. It was highly specific inasmuch as none of three known CEA-related substances, "nonspecific crossreacting antigens 1 and 2" (NCA-1 and NCA-2) and biliary glycoprotein I (BGP I), reacted in the assay. NCA

show abstract

Application of monoclonal antibodies to purified CEA in clinical radioimmunoassay of human serum

Cited by 22 publications

References 14 publications

Comparison of Monoclonal and Polyclonal Enzyme Immuno Assays for Carcinoembryonic Antigen

Comparison of Monoclonal and Polyclonal Enzyme Immuno Assays for Carcinoembryonic Antigen

Detection of Carcinoembryonic Antigen and Related Antigens in Sera of Patients with Gastrointestinal Tumors Using Monoclonal Antibodies in Double-Determinant Radioimmunoassays

A monoclonal antibody-enzyme immunoassay for serum carcinoembryonic antigen with increased specificity for carcinomas.

Contact Info

Product

Resources

About